IMBiologics (IMB) focuses on developing novel treatment options for Immunology & inflammation (I&I) diseases and cancer, utilizing innovative mechanisms of action and/or antibody platform technology, given IMB’s successful out-licensing experience. IMB’s current lead asset is an HLA-G ADC, IMB-201. HLA-G is recently known to be specifically expressed in certain solid cancers, not in normal cells. IMB-201 is proven to inhibit cancer progression in animal models, potentially by enhancing anti-tumor activity of immune cells. IMB developed a proprietary multivalent antibody platform, ePENDY, designed to overcome current limitations of IgG. Due to IgG’s limitation in avidity, certain targets, which need clustering and are low expressed, need multivalent modality. ePENDY has multiple differentiation points such as muti-valency, high avidity, long half-life and easy manufacturing. IMB- 402 is an IMB’s lead asset utilizing ePENDY designed as a dendritic cell mimetic antibody for Glioblastoma.